Efecto de la suplementación con maca (Lepidium meyenii) sobre la libido y algunas características del semen en carneros de pelo (Ovis aries)

El propósito del presente estudio fue el evaluar el efecto de la suplementación con maca (Lepidium meyenii) sobre la libido y características del semen de carneros de pelo (Ovis aries). Treinta machos Santa cruz con 15 meses de edad se alimentaron con una dieta control (alimento concentrado; n=15) durante 16 semanas o con una dieta suplementada con maca (233 mg de hipocótilos secos de maca negra/kg de peso vivo/día, integrados al alimento concentrado) durante 8 semanas, seguidas de 8 semanas sin suplementación de maca (n=15). La suplementación con maca incrementó (P<0.05) el número de montas y eyaculados disminuyendo el tiempo entre estos eventos al final de la semana ocho. Sin embargo, no se encontraron diferencias en el tiempo de reacción, tiempo al 1er eyaculado, circunferencia escrotal, volumen del eyaculado, concentración espermática ni eficiencia del carnero (montas/eyaculaciones). Efectos que persistieron ocho semanas después, sin suplementación alguna. Se concluye que el consumo de maca incrementa las conductas de cópula en los carneros de pelo, mientras que las características de semen parecen sin cambios

Universal mental health screening with a focus on suicidal behaviour using smartphones in a Mexican rural community: Protocol for the SMART-SCREEN population-based survey

Introduction Mental disorders represent the second cause of years lived with disability worldwide. Suicide mortality has been targeted as a key public health concern by the WHO. Smartphone technology provides a huge potential to develop massive and fast surveys. Given the vast cultural diversity of Mexico and its abrupt orography, smartphone-based resources are invaluable in order to adequately manage resources, services and preventive measures in the population. The objective of this study is to conduct a universal suicide risk screening in a rural area of Mexico, measuring also other mental health outcomes such as depression, anxiety and alcohol and substance use disorders. Methods and analysis A population-based cross-sectional study with a temporary sampling space of 9 months will be performed between September 2019 and June 2020. We expect to recruit a large percentage of the target population (at least 70%) in a short-term survey of Milpa Alta Delegation, which accounts for 137 927 inhabitants in a territorial extension of 288 km 2. They will be recruited via an institutional call and a massive public campaign to fill in an online questionnaire through mobile-assisted or computer-assisted web app. This questionnaire will include data on general health, validated questionnaires including Well-being Index 5, Patient Health Questionnaire-9, Generalized Anxiety Disorder Scale 2, Alcohol Use Disorders Identification Test, selected questions of the Drug Abuse Screening Test and Columbia-Suicide Severity Rating Scales and Diagnostic and statistical manual of mental disorders (DSM-5) questions about self-harm. We will take into account information regarding time to mobile app response and geo-spatial location, and aggregated data on social, demographical and environmental variables. Traditional regression modelling, multilevel mixed methods and data-driven machine learning approaches will be used to test hypotheses regarding suicide risk factors at the individual and the population level. Ethics and dissemination Ethical approval (002/2019) was granted by the Ethics Review Board of the Hospital Psiquiátrico Yucatán, Yucatán (Mexico). This protocol has been registered in ClinicalTrials.gov. The starting date of the study is 3 September 2019. Results will serve for the planning and healthcare of groups with greater mental health needs and will be disseminated via publications in peer-reviewed journal and presented at relevant mental health conferences. Trial registration number NCT04067063

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

My Life My Story

Medical Schoolhttp://deepblue.lib.umich.edu/bitstream/2027.42/171687/1/LaVana_Greene_1.pdfhttp://deepblue.lib.umich.edu/bitstream/2027.42/171687/2/LaVana_Greene_2.ppt

Recording and Playback of Collaborative Desktops on the Internet

This paper presents a Tcl/Tk recording/playback architecture and implementation that records, plays back and executes a Tcl/Tk collaborative Internet-based desktop. Specifically, the desktop brings together distributed data, application workflows, and teams into collaborative sessions in which the control of the desktop editing and execution is shared. A typical workflow invokes distributed tools and data to support the design of microelectronic systems. We argue that recording and playback of collaborative user interactions can have a wide-range of applications, such as: `keeping minutes' of interactive discussions, clicks of menuspecific commands associated with different tools on the shared desktop, user-entered data and control inputs, user-queried data outputs, support for automated software documentation, tutorials, collaborative playback of tutorials and solutions recorded earlier, etc. The summary of 540 Internet-based experiments, each relying on RecordTaker and PlaybackMaker ..